Atropine vs. Glycopyrrolate

Introduction #

Atropine and glycopyrrolate are widely used anticholinergic medications that block the action of acetylcholine at muscarinic receptors throughout the body. While they share many pharmacological properties and clinical applications, they also possess distinct characteristics that influence their selection for specific clinical scenarios. This article examines their similarities and differences in pharmacology, clinical applications, and adverse effect profiles.

Pharmacology #

Both atropine and glycopyrrolate are competitive antagonists at muscarinic acetylcholine receptors (mAChRs), which are G-protein coupled receptors found in various tissues throughout the body. There are five subtypes of muscarinic receptors (M₁-M₅), and both drugs bind to all subtypes, though with varying affinities[1].

Atropine, derived from the belladonna plant (Atropa belladonna), is a naturally occurring tertiary amine. In contrast, glycopyrrolate is a synthetic quaternary ammonium compound. This structural difference accounts for many of their pharmacokinetic variations[2].

The most significant pharmacokinetic difference between these agents is their ability to cross the blood-brain barrier (BBB). As a tertiary amine, atropine readily crosses the BBB, producing central nervous system effects. Glycopyrrolate, being a quaternary ammonium compound, has limited BBB penetration and produces minimal central effects[3].

Atropine has a shorter half-life (approximately 2-3 hours) compared to glycopyrrolate (approximately 1.7-3.5 hours). However, the duration of the primary clinical effect (treatment of bradycardia) is generally much shorter and elimination half-life is usually not a consideration in selection. Atropine is metabolized hepatically and excreted renally, while glycopyrrolate undergoes minimal metabolism and is primarily excreted unchanged in urine and bile[4].

Mechanism of Action #

Both drugs competitively antagonize muscarinic acetylcholine receptors, preventing acetylcholine from binding to these receptors. This inhibition affects parasympathetic nervous system function, leading to various physiological effects[5]:

• M₁ receptors (found in CNS and gastric parietal cells): Blockade reduces gastric acid secretion and affects memory and cognition (primarily with atropine).
• M₂ receptors (cardiac tissue): Blockade increases heart rate by inhibiting vagal tone.
• M₃ receptors (smooth muscle, glands): Blockade reduces secretions from salivary glands, bronchial glands, and sweat glands, and relaxes smooth muscle in the GI tract, urinary bladder, and bronchi.

Clinical Applications #

Both medications share several clinical uses but may be preferred in different scenarios based on their pharmacokinetic and pharmacodynamic profiles[6,7]:

Shared applications:

• Preoperative medication: Reduce secretions during surgery and anesthesia
• Reversal of neuromuscular blockade: Often combined with neostigmine to prevent or treat salivation, lacrimation, bradycardia, diarrhea associated with increased acetylcholine
• Management of bradyarrhythmias: Treatment of symptomatic bradycardia
• Antidote for cholinergic toxicity: Treatment of organophosphate poisoning

Preferential use of atropine:

• Advanced cardiac life support (ACLS): First-line for symptomatic bradycardia in emergency settings
• Organophosphate poisoning: Preferred due to CNS penetration to counteract central effects
• Pediatric bradycardia: More commonly used in pediatric resuscitation
• Ophthalmic applications: Mydriasis and cycloplegia

Preferential use of glycopyrrolate:

• Prevention of bradycardia during surgery: Often preferred in routine use due to less likelihood of tachycardia
• Drooling in neurological disorders: Particularly in hypersalivation postoperatively due to opioid administration

Paradoxical Transient Arrhythmias #

Both atropine and glycopyrrolate can paradoxically cause transient arrhythmias during onset of action. This phenomenon is particularly observed with low doses of atropine (less than 0.5 mg) and has been reported with glycopyrrolate as well[8,9].

The proposed mechanism for this effect involves differential blockade of presynaptic muscarinic receptors at low concentrations. At low doses, these drugs may preferentially block presynaptic M₁ autoreceptors in the vagal nerve, which normally inhibit acetylcholine release. This blockade leads to increased acetylcholine release at the postsynaptic junction, temporarily enhancing parasympathetic effects before sufficient postsynaptic muscarinic receptor blockade occurs[10].

This paradoxical effect typically manifests as transient bradycardia or atrioventricular block before the expected tachycardia develops. For this reason, guidelines recommend administering a minimum of 0.02 mg/kg of atropine for bradycardia treatment to avoid this paradoxical response[11].

Adverse Effects #

The adverse effect profiles of both medications are related to their antimuscarinic actions but differ in certain aspects due to their pharmacokinetic differences[12,13]:

Shared adverse effects:

• Cardiovascular: Tachycardia, palpitations, prolonged QT interval
• Gastrointestinal: Dry mouth, constipation, dysphagia
• Genitourinary: Urinary retention, urinary hesitancy
• Ophthalmologic: Blurred vision, photophobia, increased intraocular pressure

More prominent with atropine:

• CNS effects: Confusion, agitation, hallucinations, delirium, especially in elderly

More prominent with glycopyrrolate:

• Peripheral anticholinergic effects: Often more pronounced dry mouth and decreased secretions
• Less CNS toxicity: Preferred in elderly patients due to reduced risk of delirium

Dosing Considerations #

Atropine is typically dosed at 0.02-0.04 mg/kg IV for bradycardia, while glycopyrrolate is often used at 0.05-0.0.1 mg/kg IV.

The lower dose required for glycopyrrolate reflects its higher potency at peripheral muscarinic receptors compared to atropine.

Conclusion #

While atropine and glycopyrrolate share the fundamental mechanism of muscarinic receptor antagonism, their structural and pharmacokinetic differences lead to distinct clinical profiles. The limited BBB penetration of glycopyrrolate makes it preferable when CNS side effects are a concern, while atropine’s CNS activity is advantageous in certain scenarios like organophosphate poisoning. Both can cause paradoxical arrhythmias during onset, reflecting the complex nature of cholinergic regulation in the cardiovascular system. The selection between these agents should be tailored to specific clinical circumstances, patient characteristics, and desired duration of action.

References #

1. Brown JH, Laiken N. Muscarinic receptor agonists and antagonists. In: Brunton LL, et al. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill; 2018.
2. Katzung BG. Cholinoceptor-blocking drugs. In: Basic & Clinical Pharmacology. 14th ed. McGraw-Hill; 2018.
3. Ali-Melkkilä T, Kanto J, Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand. 1993;37(7):633-642.
4. Mirakhur RK, Dundee JW. Glycopyrrolate: pharmacology and clinical use. Anaesthesia. 1983;38(12):1195-1204.
5. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987;237(4814):527-532.
6. Pappano AJ, Wier WG. Cholinoceptor-blocking drugs. In: Cardiovascular Pharmacology. 11th ed. Elsevier; 2019.
7. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50(2):279-290.
8. Bernheim A, Fatio R, Kiowski W, et al. Atropine often results in complete atrioventricular block or sinus arrest after cardiac transplantation: an unpredictable and dose-independent phenomenon. Transplantation. 2004;77(8):1181-1185.
9. Gupta S, Choudhary M, Sadana N. Glycopyrrolate induced ventricular tachycardia in a pediatric patient: A rare adverse effect. World J Clin Cases. 2019;7(17):2608-2612.
10. Hartikainen J, Ahonen E, Nevalainen T, et al. Dual effect of muscarinic receptor blockade on heart rate in humans. Clin Auton Res. 1996;6(4):199-204.
11. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(18 Suppl 2):S444-S464.
12. Thal GD, Szabo MD. Atropine versus glycopyrrolate: what’s the difference? AANA J. 1985;53(3):270-271.
13. Lahiri S, Ashok V, Choudhury SR, Saxena A. Comparing the efficacy of atropine and glycopyrrolate in prevention of bradycardia and hypotension following laryngoscopy and endotracheal intubation. Anesth Essays Res. 2019;13(2):284-288.
14. Chamorro C, Borrallo JM, Romera MA, et al. Anesthesia and analgesia protocol during therapeutic hypothermia after cardiac arrest: a systematic review. Anesth Analg. 2010;110(5):1328-1335.